Annovis Bio
ANVS
53 hedge funds and large institutions have $14.7M invested in Annovis Bio in 2025 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 17 increasing their positions, 2 reducing their positions, and 8 closing their positions.
750% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 2
250% more capital invested
Capital invested by funds: $4.19M → $14.7M (+$10.5M)
162% more call options, than puts
Call options by funds: $2.01M | Put options by funds: $768K
150% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 8
26% more funds holding
Funds holding: 42 → 53 (+11)
5.6% more ownership
Funds ownership: 10.39% → 15.99% (+5.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$2.18M |
| 2 |
Two Sigma Investments
New York
|
+$1.66M |
| 3 |
Jane Street
New York
|
+$755K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$557K |
| 5 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
+$483K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$524K |
| 2 |
HF
HRT Financial
New York
|
-$77K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$59.7K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$21.8K |
| 5 |
GWM
Greenwich Wealth Management
Greenwich,
Connecticut
|
-$15K |
ANVS Hedge Fund Activity: Q4 2025 in Review
53 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in Annovis Bio (ANVS) for Q4 2025, worth a combined $14.7M — up 250% from $4.19M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ANVS positions and 8 closed out — a net gain of 12 holders — while 17 added to existing stakes and 2 trimmed.
The largest buyer was Marshall Wace, opening a new position worth an estimated $2.18M. The largest seller was Citadel Advisors, exiting entirely with an estimated $524K sold.
- 53 institutional investors held Annovis Bio (ANVS) as of Q4 2025, up from 42 in Q3 2025.
- Funds reported $14.7M of Annovis Bio stock for Q4 2025, up 250% quarter-over-quarter.
- 20 funds opened new Annovis Bio positions in Q4 2025 and 8 closed out, a net change of +12 holders.
- The largest Annovis Bio buyer in Q4 2025 was Marshall Wace, an estimated $2.18M added.
- The largest Annovis Bio seller in Q4 2025 was Citadel Advisors, an estimated $524K sold.
Based on aggregated 13F filings for Q4 2025.